Alps Advisors Inc. acquired a new stake in shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 24,979 shares of the company’s stock, valued at approximately $246,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of SNDX. Wellington Management Group LLP purchased a new position in Syndax Pharmaceuticals during the first quarter valued at approximately $17,557,000. Tiverton Asset Management LLC purchased a new position in Syndax Pharmaceuticals during the first quarter valued at approximately $3,846,000. Cormorant Asset Management LLC purchased a new position in Syndax Pharmaceuticals during the first quarter valued at approximately $2,856,000. BlackRock Group LTD purchased a new position in Syndax Pharmaceuticals during the first quarter valued at approximately $2,379,000. Finally, BlackRock Inc. purchased a new position in Syndax Pharmaceuticals during the first quarter valued at approximately $594,000. 57.64% of the stock is owned by hedge funds and other institutional investors.
Shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) traded down 2.26% during mid-day trading on Friday, hitting $14.28. The company’s stock had a trading volume of 71,890 shares. Syndax Pharmaceuticals Inc. has a 12-month low of $8.97 and a 12-month high of $18.03. The company’s market cap is $253.93 million. The stock has a 50-day moving average of $14.35 and a 200-day moving average of $13.55.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. On average, equities research analysts forecast that Syndax Pharmaceuticals Inc. will post ($3.01) EPS for the current year.
SNDX has been the subject of several recent research reports. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Guggenheim started coverage on Syndax Pharmaceuticals in a research note on Friday, October 7th. They issued a “buy” rating and a $29.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $25.80.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc. (NASDAQ:SNDX).
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.